MCID: UTR011
MIFTS: 45

Uterine Corpus Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Serous Adenocarcinoma

MalaCards integrated aliases for Uterine Corpus Serous Adenocarcinoma:

Name: Uterine Corpus Serous Adenocarcinoma 12 15
Uterine Papillary Serous Carcinoma 12
Endometrial Serous Adenocarcinoma 73
Uterine Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5750
NCIt 50 C27838
UMLS 73 C1336921

Summaries for Uterine Corpus Serous Adenocarcinoma

Disease Ontology : 12 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary : Uterine Corpus Serous Adenocarcinoma, also known as uterine papillary serous carcinoma, is related to adenocarcinoma and carcinosarcoma. An important gene associated with Uterine Corpus Serous Adenocarcinoma is TUBB3 (Tubulin Beta 3 Class III), and among its related pathways/superpathways are TGF-Beta Pathway and Class I MHC mediated antigen processing and presentation. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and brain, and related phenotypes are Decreased CDKN1A mRNA expression and Decreased CDKN1A mRNA expression

Related Diseases for Uterine Corpus Serous Adenocarcinoma

Diseases related to Uterine Corpus Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.3 ERBB2 PIK3CA TP53
2 carcinosarcoma 30.0 ERBB2 PIK3CA TP53
3 endometrial cancer 29.9 BRCA1 ERBB2 PIK3CA TP53
4 ovarian cancer 1 29.6 BRCA1 ERBB2 PIK3CA TP53
5 uterine carcinosarcoma 29.3 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
6 spinal cord glioma 10.2 TP53 TUBB3
7 ovarian carcinosarcoma 10.2 ERBB2 TUBB3
8 gastric papillary adenocarcinoma 10.2 ERBB2 TP53
9 papillary adenocarcinoma 10.2 ERBB2 TP53
10 prostate squamous cell carcinoma 10.1 PPP2R1A TP53
11 pleomorphic adenoma carcinoma 10.1 ERBB2 TP53
12 non-proliferative fibrocystic change of the breast 10.1 ERBB2 TP53
13 glioma susceptibility 1 10.1 ERBB2 TP53
14 microglandular adenosis 10.1 ERBB2 TP53
15 adult medulloblastoma 10.1 TP53 TUBB3
16 adult hepatocellular carcinoma 10.1 PIK3CA TP53
17 esophagus adenocarcinoma 10.1 ERBB2 TP53
18 rare adenocarcinoma of the breast 10.1 PIK3CA TP53
19 malignant spiradenoma 10.1 PIK3CA TP53
20 breast benign neoplasm 10.1 ERBB2 TP53
21 thoracic benign neoplasm 10.1 ERBB2 TP53
22 granulosa cell tumor of the ovary 10.1 ERBB2 TP53
23 hidradenocarcinoma 10.1 ERBB2 TP53
24 tonsil cancer 10.1 ERBB2 TP53
25 barrett's adenocarcinoma 10.1 ERBB2 TP53
26 insulin-like growth factor i 10.1
27 acneiform dermatitis 10.1 ERBB2 PIK3CA
28 skin squamous cell carcinoma 10.1 PIK3CA TP53
29 epithelial-myoepithelial carcinoma 10.1 FBXW7 TP53
30 breast cancer 10.1
31 pulmonary fibrosis 10.1
32 ovarian serous carcinoma 10.1
33 lymphoma 10.1
34 thrombocytosis 10.1
35 endometrial adenocarcinoma 10.1
36 cervix carcinoma 10.1
37 penile cancer 10.0 PIK3CA TP53
38 adenosquamous lung carcinoma 10.0 ERBB2 PIK3CA
39 esophageal disease 10.0 ERBB2 TP53
40 stomach disease 10.0 ERBB2 TP53 TUBB3
41 brain stem glioma 10.0 PIK3CA TP53
42 mixed cell type cancer 10.0 ERBB2 PPP2R1A TP53
43 synchronous bilateral breast carcinoma 10.0 BRCA1 TP53
44 papillary serous adenocarcinoma 10.0 BRCA1 TP53
45 adenosquamous carcinoma 10.0 PIK3CA TP53
46 glycogen-rich clear cell breast carcinoma 10.0 BRCA1 TP53
47 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.0 PIK3CA PPP2R1A TP53
48 tuberculous salpingitis 10.0 BRCA1 ERBB2
49 ovarian clear cell carcinoma 10.0 PIK3CA PPP2R1A TP53
50 breast medullary carcinoma 10.0 BRCA1 ERBB2

Graphical network of the top 20 diseases related to Uterine Corpus Serous Adenocarcinoma:



Diseases related to Uterine Corpus Serous Adenocarcinoma

Symptoms & Phenotypes for Uterine Corpus Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased CDKN1A mRNA expression GR00389-S-1 9.13 FBXW7 TP53
2 Decreased CDKN1A mRNA expression GR00389-S-2 9.13 TP53
3 Increased cell death HMECs cells GR00103-A-0 9.02 BRCA1 FBXW7 PIK3CA PPP2R1A TP53

MGI Mouse Phenotypes related to Uterine Corpus Serous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.95 BRCA1 ERBB2 FBXW7 KIAA1324 PIK3CA TP53
2 behavior/neurological MP:0005386 9.91 BRCA1 ERBB2 KIAA1324 PIK3CA PPP2R1A TP53
3 homeostasis/metabolism MP:0005376 9.87 BRCA1 ERBB2 FBXW7 KIAA1324 PIK3CA PPP2R1A
4 embryo MP:0005380 9.77 BRCA1 ERBB2 FBXW7 PIK3CA TP53
5 mortality/aging MP:0010768 9.76 BRCA1 ERBB2 FBXW7 KIAA1324 PIK3CA PPP2R1A
6 integument MP:0010771 9.65 BRCA1 ERBB2 FBXW7 PIK3CA TP53
7 neoplasm MP:0002006 9.43 BRCA1 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
8 respiratory system MP:0005388 9.02 BRCA1 ERBB2 FBXW7 TP53 TUBB3

Drugs & Therapeutics for Uterine Corpus Serous Adenocarcinoma

Drugs for Uterine Corpus Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
4
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 46835353 6436030 5284616
7
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
9
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
10
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
11
Doxil Approved June 1999 Phase 3,Phase 1 31703
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
13 Antimitotic Agents Phase 3,Phase 2,Phase 1
14 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
15 Immunologic Factors Phase 3,Phase 2,Phase 1
16 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 1
18 Adjuvants, Immunologic Phase 3,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antifungal Agents Phase 2, Phase 3
21 Anti-Infective Agents Phase 2, Phase 3,Phase 1
22 Immunosuppressive Agents Phase 2, Phase 3
23 Hypoglycemic Agents Phase 2, Phase 3
24 Estrogen Antagonists Phase 2, Phase 3
25 Steroid Synthesis Inhibitors Phase 2, Phase 3
26 Estrogens Phase 2, Phase 3
27 Hormones Phase 2, Phase 3
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
29 Hormone Antagonists Phase 2, Phase 3
30 Aromatase Inhibitors Phase 2, Phase 3
31 Estrogen Receptor Antagonists Phase 2, Phase 3
32
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
33
Nintedanib Approved Phase 2 656247-17-5 56843413
34
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
35
Olaparib Approved Phase 2 763113-22-0 23725625
36
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
37
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
38
Maleic acid Experimental Phase 2 110-16-7 444266
39
Cediranib Investigational Phase 2 288383-20-0 9933475
40
Trebananib Investigational Phase 2 894356-79-7
41 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
42 Protein Kinase Inhibitors Phase 1, Phase 2,Phase 2
43 Immunoglobulins Phase 2,Phase 1
44 Immunoglobulin G Phase 2,Phase 1
45 Antibodies Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 2,Phase 1
47 Antibodies, Monoclonal Phase 2,Phase 1
48 Mitogens Phase 2,Phase 1
49 Angiogenesis Inhibitors Phase 2,Phase 1
50 Endothelial Growth Factors Phase 2,Phase 1

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
2 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
3 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
4 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
5 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
6 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
7 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
8 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
9 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
10 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
11 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
12 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
13 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
14 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
15 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
16 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
17 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
18 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
19 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
20 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
21 A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Recruiting NCT02491099 Phase 2 Afatinib
22 AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma Recruiting NCT03668340 Phase 2 AZD1775
23 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
24 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
25 Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Recruiting NCT03660826 Phase 2 Cediranib Maleate;Olaparib
26 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
27 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
28 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Suspended NCT02728258 Phase 2 Copanlisib
29 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
30 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
31 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
32 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
33 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
34 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
35 Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer Recruiting NCT03325634 Phase 1
36 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Recruiting NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
37 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting NCT03552471 Phase 1 Rucaparib Camsylate
38 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 1 Trametinib;Uprosertib
39 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
40 PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer Active, not recruiting NCT01737619 Not Applicable Indocyanine Green Solution
41 Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery Active, not recruiting NCT02315469
42 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837

Search NIH Clinical Center for Uterine Corpus Serous Adenocarcinoma

Genetic Tests for Uterine Corpus Serous Adenocarcinoma

Anatomical Context for Uterine Corpus Serous Adenocarcinoma

MalaCards organs/tissues related to Uterine Corpus Serous Adenocarcinoma:

41
Cervix, Lung, Brain, Bone, Ovary, Spinal Cord, Pancreas

Publications for Uterine Corpus Serous Adenocarcinoma

Articles related to Uterine Corpus Serous Adenocarcinoma:

(show top 50) (show all 154)
# Title Authors Year
1
Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma. ( 29958235 )
2018
2
Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases. ( 30464593 )
2018
3
Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study. ( 27668395 )
2017
4
Sonographic depiction of non-palpable uterine papillary serous carcinoma metastasis embedded within the abdominal wall. ( 27683188 )
2017
5
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. ( 28062116 )
2017
6
Utility of radiation therapy for early-stage uterine papillary serous carcinoma. ( 28343693 )
2017
7
Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital. ( 27266220 )
2016
8
The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. ( 26463437 )
2016
9
Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp. ( 26535985 )
2016
10
Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study. ( 26537059 )
2016
11
Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases. ( 26588230 )
2016
12
Adrenal Metastasis from Uterine Papillary Serous Carcinoma. ( 27117594 )
2016
13
Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma. ( 27514313 )
2016
14
Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution. ( 25470688 )
2015
15
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. ( 25575483 )
2015
16
Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. ( 25641568 )
2015
17
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy. ( 25695549 )
2015
18
Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary? ( 26235227 )
2015
19
Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. ( 24211401 )
2014
20
Case of uterine papillary serous carcinoma following tamoxifen treatment that could not be diagnosed during screening. ( 24606575 )
2014
21
Abdominal wall metastasis of uterine papillary serous carcinoma in a post-menopausal woman: a case report. ( 25371890 )
2014
22
Pulmonary fibrosis after pegylated liposomal Doxorubicin in a patient with uterine papillary serous carcinoma. ( 23358980 )
2013
23
Decreased expression of 14-3-3I8 is predictive of poor prognosis for patients with human uterine papillary serous carcinoma. ( 24201220 )
2013
24
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. ( 23385150 )
2013
25
Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. ( 24055615 )
2013
26
Excellent Response to Palliative Chemotherapy for Pleural Recurrence of Uterine Papillary Serous Carcinoma. ( 29147358 )
2013
27
Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. ( 22865295 )
2012
28
Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. ( 22035806 )
2012
29
Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. ( 22237383 )
2012
30
Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. ( 22329832 )
2012
31
Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. ( 22679564 )
2012
32
Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study. ( 22976496 )
2012
33
Her-2 targeting in uterine papillary serous carcinoma. ( 24371631 )
2012
34
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. ( 21126755 )
2011
35
Clinical management of uterine papillary serous carcinoma. ( 21166512 )
2011
36
Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. ( 21436701 )
2011
37
Optimal surgical debulking in uterine papillary serous carcinoma affects survival. ( 21440290 )
2011
38
Uterine papillary serous carcinoma. ( 21508697 )
2011
39
Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? ( 21525737 )
2011
40
Clinicopathological characteristics and her-2/neu status in chinese patients with uterine papillary serous carcinoma. ( 21647234 )
2011
41
The importance of chemotherapy and radiation in uterine papillary serous carcinoma. ( 21963091 )
2011
42
[Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma]. ( 20646447 )
2010
43
Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. ( 19952744 )
2010
44
Retroperitoneal tuberculosis in a patient with uterine papillary serous carcinoma. ( 20060636 )
2010
45
Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience. ( 20129252 )
2010
46
Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. ( 20691465 )
2010
47
Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma. ( 20944161 )
2010
48
Uterine papillary serous carcinoma metastatic to the choroid. ( 25390124 )
2010
49
Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. ( 19476987 )
2009
50
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. ( 19118888 )
2009

Variations for Uterine Corpus Serous Adenocarcinoma

Copy number variations for Uterine Corpus Serous Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA Uterine serous papillary cancer

Expression for Uterine Corpus Serous Adenocarcinoma

Search GEO for disease gene expression data for Uterine Corpus Serous Adenocarcinoma.

Pathways for Uterine Corpus Serous Adenocarcinoma

Pathways related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 BRCA1 ERBB2 PIK3CA PPP2R1A TP53
2
Show member pathways
13.13 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
3
Show member pathways
12.87 ERBB2 PIK3CA PPP2R1A TP53
4
Show member pathways
12.47 BRCA1 ERBB2 PIK3CA TP53
5
Show member pathways
12.44 BRCA1 ERBB2 PIK3CA TP53
6
Show member pathways
12.39 BRCA1 ERBB2 PIK3CA PPP2R1A TP53
7
Show member pathways
12.37 ERBB2 PIK3CA TP53
8
Show member pathways
12.37 ERBB2 PIK3CA PPP2R1A TP53
9
Show member pathways
12.32 ERBB2 PIK3CA TP53
10 12.29 BRCA1 PPP2R1A TP53
11
Show member pathways
12.28 ERBB2 PIK3CA TP53
12
Show member pathways
12.25 ERBB2 PIK3CA TP53
13
Show member pathways
12.2 PIK3CA PPP2R1A TP53
14
Show member pathways
12.2 ERBB2 PIK3CA TP53
15
Show member pathways
12.16 FBXW7 TP53 TUBB3
16 12.1 BRCA1 ERBB2 PIK3CA TP53
17 12.03 ERBB2 PIK3CA TP53
18
Show member pathways
11.98 ERBB2 PIK3CA TP53
19 11.87 ERBB2 PIK3CA TP53
20 11.8 PIK3CA PPP2R1A TP53
21
Show member pathways
11.73 ERBB2 PIK3CA TP53
22 11.65 PIK3CA PPP2R1A TP53
23 11.6 ERBB2 PIK3CA TP53
24 11.39 PIK3CA TP53
25 11.37 BRCA1 TP53
26 11.31 BRCA1 TP53
27 11.29 BRCA1 TP53
28 11.25 ERBB2 PIK3CA TP53
29 11.12 BRCA1 ERBB2 PIK3CA TP53
30 11.1 BRCA1 TP53
31 11.08 ERBB2 PIK3CA
32 11.07 BRCA1 TP53
33 11.03 BRCA1 TP53
34 10.84 BRCA1 ERBB2 FBXW7 PIK3CA TP53
35 10.8 BRCA1 TP53

GO Terms for Uterine Corpus Serous Adenocarcinoma

Biological processes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase signaling GO:0014065 9.32 ERBB2 PIK3CA
2 ERBB2 signaling pathway GO:0038128 9.26 ERBB2 PIK3CA
3 positive regulation of cell cycle arrest GO:0071158 9.16 BRCA1 TP53
4 vasculature development GO:0001944 8.96 FBXW7 PIK3CA
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.62 BRCA1 TP53

Molecular functions related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 8.8 BRCA1 FBXW7 TP53

Sources for Uterine Corpus Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....